William Hildebrand to Immunotherapy
This is a "connection" page, showing publications William Hildebrand has written about Immunotherapy.
Connection Strength
0.613
-
Expanding the targets available to therapeutic antibodies via novel disease-specific markers. Int Rev Immunol. 2011 Oct-Dec; 30(5-6):312-27.
Score: 0.324
-
Antigen presentation and interferon signatures in B cells driven by localized ablative cancer immunotherapy correlate with extended survival. Theranostics. 2022; 12(2):639-656.
Score: 0.165
-
TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells. Int Rev Immunol. 2011 Oct-Dec; 30(5-6):328-40.
Score: 0.081
-
Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors. J Immunother Cancer. 2022 Oct; 10(10).
Score: 0.043